02.20.20

AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdown

Source: FiercePharma

AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against the combo, according to a FiercePharma report.

Despite AbbVie’s assurances that divesting brazikumab would help level the competitive playing field after its $63 billion megamerger with Allergan, the proposed sale would not accomplish that goal, the groups told the Federal Trade Commission (FTC) in a letter (PDF) Tuesday. 

Read the full article.

 

Related Content